OTCMKTS:SGIOY Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis $11.32 +0.07 (+0.62%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$10.86▼$11.3750-Day Range$9.35▼$11.3252-Week Range$9.33▼$13.67Volume49,377 shsAverage Volume109,221 shsMarket Capitalization$13.43 billionP/E Ratio11.67Dividend Yield1.59%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get Shionogi & Co., Ltd. alerts: Email Address Shionogi & Co., Ltd. MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthModerateBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth-2.08%From $0.96 to $0.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.96 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Shionogi & Co., Ltd..Read more about Shionogi & Co., Ltd.'s stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of Shionogi & Co., Ltd. have been sold short.Short Interest Ratio / Days to CoverShionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shionogi & Co., Ltd. has recently increased by 2,600.00%, indicating that investor sentiment is decreasing significantly. Previous Next 2.5 Dividend Strength Dividend YieldShionogi & Co., Ltd. pays a meaningful dividend of 1.64%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthShionogi & Co., Ltd. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Shionogi & Co., Ltd. is 18.56%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Shionogi & Co., Ltd. will have a dividend payout ratio of 19.15% next year. This indicates that Shionogi & Co., Ltd. will be able to sustain or increase its dividend.Read more about Shionogi & Co., Ltd.'s dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGIOY. Previous Next 2.2 News and Social Media Coverage News SentimentShionogi & Co., Ltd. has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.92% of the stock of Shionogi & Co., Ltd. is held by institutions.Read more about Shionogi & Co., Ltd.'s insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Shionogi & Co., Ltd. are expected to decrease by -2.08% in the coming year, from $0.96 to $0.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shionogi & Co., Ltd. is 11.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Shionogi & Co., Ltd. is 11.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.35.Price to Earnings Growth RatioShionogi & Co., Ltd. has a PEG Ratio of 2.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioShionogi & Co., Ltd. has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOY)Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.Read More SGIOY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGIOY Stock News HeadlinesAugust 14, 2024 | americanbankingnews.comShionogi & Co., Ltd. (OTCMKTS:SGIOY) Sees Significant Increase in Short InterestJuly 30, 2024 | seekingalpha.comShionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call TranscriptAugust 22, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…July 29, 2024 | markets.businessinsider.comShionogi earnings preview: what to expectMay 14, 2024 | msn.comShionogi & Co. reports FY resultsMay 13, 2024 | msn.comJapan's Shionogi says COVID treatment did not meet endpoint in late-stage trialMay 12, 2024 | markets.businessinsider.comWhat Wall Street expects from Shionogi's earningsMay 10, 2024 | bizjournals.comRegulators caused breakup of potential $750 million drug deal — now they've blessed company's latest moveAugust 22, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…May 10, 2024 | finance.yahoo.comShionogi secures licence for Maze’s Pompe disease treatmentMay 8, 2024 | msn.comTeva hits a five-year high on schizophrenia trial win, Q1 beatMarch 18, 2024 | seekingalpha.comSGIOY Shionogi & Co., Ltd.February 15, 2024 | wsj.comShionogi & Co. Ltd. ADRFebruary 1, 2024 | uk.investing.comShionogi & Co., Ltd. (4507)February 1, 2024 | markets.businessinsider.comHere's what to expect from Shionogi's earningsFebruary 1, 2024 | msn.comShionogi & Co. GAAP EPS of ¥435.74, revenue of ¥336.82BDecember 18, 2023 | msn.comShionogi commences Phase III monovalent Covid-19 vaccine trialDecember 17, 2023 | msn.comShionogi & Co. - ADR (SGIOY) Price Target Increased by 14.91% to 16.05See More Headlines Receive SGIOY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2024Today8/22/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryPersonal Services Current SymbolOTCMKTS:SGIOY CUSIPN/A CIK1281721 Webwww.shionogi.co.jp Phone(166) 202-2161FaxN/AEmployees5,680Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.97 Trailing P/E Ratio11.67 Forward P/E Ratio11.79 P/E Growth2.33Net Income$1.12 billion Net Margins35.53% Pretax Margin45.57% Return on Equity11.95% Return on Assets10.56% Debt Debt-to-Equity Ratio0.01 Current Ratio5.86 Quick Ratio5.37 Sales & Book Value Annual Sales$3.01 billion Price / Sales4.46 Cash Flow$1.09 per share Price / Cash Flow10.42 Book Value$7.29 per share Price / Book1.55Miscellaneous Outstanding Shares1,186,180,000Free FloatN/AMarket Cap$13.43 billion OptionableNot Optionable Beta0.22 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Isao Teshirogi Ph.D. (Age 65)CEO, President & Representative Director Comp: $1.84MSusumu MitsumoriVice President of Finance & Accounting DepartmentMr. Kazuhiro HatanakaSenior Executive Officer & Senior VP of Administration DivisionMr. Takeshi Shiota Ph.D.Corporate Officer and Senior VP of Corporate Quality Assurance, Ethics & Compliance Management Div.Mr. Yoshimasa KyokawaVice President of Corporate Communications & Secretary OfficeYoshihiro FuruyaVice President of General Marketing and Compliance Officer of Corporate GXP Compliance OfficeMr. Kohji Hanasaki Ph.D.Senior Executive Officer and Senior VP of Supply Supervisory Unit & Global Business DivisionDr. John A. Keller Ph.D. (Age 59)Senior Executive Officer and Senior VP of R&D Supervisory Unit Akira Kato Ph.D.Corporate Officer & President of Shionogi Pharma Co., LtdDr. Ryuichi Kiyama Ph.D.Senior Executive Officer & Senior VP of Corporate Strategy DivisionMore ExecutivesKey CompetitorsDeutsche PostOTCMKTS:DHLGYHeinekenOTCMKTS:HEINYJapan TobaccoOTCMKTS:JAPAYHOYAOTCMKTS:HOCPYDENSOOTCMKTS:DNZOYView All Competitors SGIOY Stock Analysis - Frequently Asked Questions How have SGIOY shares performed this year? Shionogi & Co., Ltd.'s stock was trading at $11.9720 on January 1st, 2024. Since then, SGIOY stock has decreased by 5.4% and is now trading at $11.32. View the best growth stocks for 2024 here. How were Shionogi & Co., Ltd.'s earnings last quarter? Shionogi & Co., Ltd. (OTCMKTS:SGIOY) posted its quarterly earnings results on Monday, July, 29th. The company reported $0.17 earnings per share for the quarter. The business had revenue of $625.99 million for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a trailing twelve-month return on equity of 11.95%. How do I buy shares of Shionogi & Co., Ltd.? Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SGIOY) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shionogi & Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shionogi & Co., Ltd. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
